Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Canada Will Test MDS Proteomics Technology

NEW YORK, Jan. 14-Eli Lilly Canada will work with MDS Proteomics to evaluate PhosMap, an MDS technology that characterizes the changes in proteins that may develop during drug therapy.


Lilly will use the technology to assess the effects of kinase inhibitors on kinase targets. The collaboration is designed as a demonstration of the system.


Financial terms of the collaboration were not revealed. For further details, see the company website.


Eli Lilly Canada, headquartered in Toronto, is a division of Eli Lilly.


MDS Proteomics is a subsidiary of MDS.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more